NASDAQ:BYSIBeyondspring Stock Price, Forecast & News

Beyondspring's stock was trading at $11.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BYSI shares have increased by 39.6% and is now trading at $15.84. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beyondspring in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Beyondspring.

Beyondspring is scheduled to release its next quarterly earnings announcement on Wednesday, September 16th 2020. View our earnings forecast for Beyondspring.

Beyondspring Inc (NASDAQ:BYSI) issued its quarterly earnings results on Thursday, June, 11th. The company reported ($0.58) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.08. View Beyondspring's earnings history.

4 brokerages have issued twelve-month price objectives for Beyondspring's stock. Their forecasts range from $25.00 to $46.00. On average, they expect Beyondspring's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 121.0% from the stock's current price. View analysts' price targets for Beyondspring.

Press coverage about BYSI stock has been trending negative on Friday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Beyondspring earned a news impact score of -2.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Beyondspring.

Some companies that are related to Beyondspring include Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), Dicerna Pharmaceuticals (DRNA), Principia Biopharma (PRNB), Xencor (XNCR), Prestige Consumer Healthcare (PBH), Ligand Pharmaceuticals (LGND), Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Myovant Sciences (MYOV), Akebia Therapeutics (AKBA), I-Mab (IMAB), Intra-Cellular Therapies (ITCI), Y-mAbs Therapeutics (YMAB) and Madrigal Pharmaceuticals (MDGL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Beyondspring investors own include Exelixis (EXEL), Enterprise Products Partners (EPD), Intel (INTC), AbbVie (ABBV), Gilead Sciences (GILD), Johnson & Johnson (JNJ), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), Crispr Therapeutics (CRSP) and Enbridge (ENB).

(BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO.

Beyondspring trades on the NASDAQ under the ticker symbol "BYSI."

Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BYSI stock can currently be purchased for approximately $15.84.

Beyondspring has a market capitalization of $476.91 million. The company earns $-38,080,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.

The official website for Beyondspring is www.beyondspringpharma.com.

Beyondspring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 1-646-305-6387 or via email at [email protected]